Twitter | Search | |
Search Refresh
biosimilars101 9s
In an interview with , Wayne Winegarden, PhD, shared that "could help promote greater affordability and improve people's health and, especially, adherence because when we have greater adherence, we have greater health outcomes."
Reply Retweet Like
Biosimilars Council 38m
The healthcare system is facing unprecedented challenges, further proving the need for more approved . Today, IGBA released a paper highlighting two ways regulatory authorities can create a conducive environment for biosimilars competition:
Reply Retweet Like
CenterForBiosimilars 1h
Recent attempts at reform across the and generic drug landscape have not had unanimous support, legal experts noted at the ’s 11th Summit on & Innovator Biologics. Read more:
Reply Retweet Like
BPC 2h
According to BPC's survey, 3 in 4 patients want to know more about the risks and benefits of .
Reply Retweet Like
Stanton Mehr 3h
With US bordering on 40% uptake of oncology in year 1, "We can no longer characterize biosimilar uptake in the US as “sluggish,” says Aurelio Arias of at this morning's webinar.
Reply Retweet Like
CenterForBiosimilars 3h
Eva Temkin, acting director for policy at the OTBB, provided a snapshot of how the 's new office is faring in her keynote talk at the 's 11th Summit on & Innovator Biologics. Read more:
Reply Retweet Like
Stanton Mehr 3h
Aurerio Arias from Biosimilar Webinar: European countries' move away from winner-take-all bids to accepting multiple biosimilar tenders is helping sustain its biosimilar market.
Reply Retweet Like
Global Market Insights 9h
Join Aurelio Arias today in exploring the latest market trends and opportunities for and , discussing how with large biologic expiries few and far between, companies need to stand out in this competitive environment.
Reply Retweet Like
Liza Papautsky 14h
Please help us understand your with by taking a short, anonymous survey for people in the US with all stages of + . Please RT.
Reply Retweet Like
IQVIA Sep 22
In our upcoming webinar we'll look at the market trends for and opportunities for . Join Aurelio Arias as he shares uptake rates, pipeline activity and what the launch environment might look like in this important market:
Reply Retweet Like
ION Solutions Sep 21
Biosimilars are critical, potentially life-saving, biologic-based therapies, at more reasonable prices. Access resources for practices:
Reply Retweet Like
biosimilars101 Sep 23
Studies continue to show equivalency between and their biologic counterparts, with several new reports out from the European Society for Medical Oncology (ESMO) Virtual Congress
Reply Retweet Like
Stanton Mehr 3h
Listening to Markus Meier from explain role and potential actions in biologics/biosimilar competition at ACI's and Biologics virtual conference.
Reply Retweet Like
OncologyEducation 21h
Join this expert multi-disciplinary panel on October 14th for a discussion on the implementation of into clinical practice. Registration is free for healthcare professionals:
Reply Retweet Like
biosimilars101 3h
“The more people hear about the potentially huge cost saving with , the more Congress is going to be amenable to moving this on through." --
Reply Retweet Like
Melissa Andel Sep 22
WaPo Story on Drug Pricing Misses Opportunity to Talk Biosimilars
Reply Retweet Like
Gan & Lee Pharmaceuticals. Sep 17
We are delighted to announce our inaugural participation at . On Friday 25th September, we will be hosting a Meet-the-Expert Session. We hope you can join us. The information provided is for medical and pharmacy professionals only.
Reply Retweet Like
ACI Pharma Sep 22
Tomorrow at the virtual Summit on Biosimilars - hear from U.S. FTC, PTO and FDA officials, benchmark with key in-house and industry stakeholders and gain the best legal, regulatory and commercial strategies for the and marketplace.
Reply Retweet Like
CenterForBiosimilars Sep 23
from have demonstrated equivalency in clinical trial and real world settings, according to 2 prominent cancer specialists at , the 's Virtual Congress. Read more:
Reply Retweet Like
Malvika Vyas Sep 21
: ESMO's efforts towards & : 1⃣ -MCBS: 2⃣ : 3⃣ Development of a geographically-adapted value-based model 4⃣ :
Reply Retweet Like